Fiche traitement
CGRP
Danish Headache Center • Migraine
Suivi actif
Non applicable
Résumé
CGRP est développé par Danish Headache Center. Le traitement est actuellement en Non applicable. Il est associé à Migraine. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.
À vérifier
À vérifier
Non applicable
Danish Headache Center
Non renseigné
The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by calcitonin gene-related peptide (CGRP) compared to patients with few genetic loci associated with migraine (low genetic load).
2022-07-31
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Non applicable
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
À vérifier
Confiance automatique : 0%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT01924052, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2022-07-31
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeTerminée
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeNon applicable
Études associées1
Publications associées47
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
51 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2013-06-01 | Début de l’étudeNCT01924052 | Registre d’essai clinique |
| 2013-08-01 | Fin de l’étude prévue / enregistréeNCT01924052 | Registre d’essai clinique |
| 2022-07-31 | Dernière mise à jour des donnéesCGRP | Biomedical Watch |
| 2026-07-14 | Publication[Effect of electroacupuncture on chronic pain in patients with knee osteoarthritis and its influence on central sensitization]. | Zhongguo zhen jiu = Chinese acupuncture & moxibustion |
| 2026-07-22 | PublicationCross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry. | The journal of headache and pain |
| 2026-07-22 | PublicationLong-term treatment with Eptinezumab in special treatment situations: Real world data. | Journal of the neurological sciences |
| 2026-08-08 | PublicationEfficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. | Brain : a journal of neurology |
| 2026-08-08 | PublicationCGRP-pathway exposure during the pre-EBP interval in spontaneous intracranial hypotension: an exploratory retrospective case series. | BMC neurology |
| 2026-08-08 | PublicationComparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when? | Expert review of neurotherapeutics |
| 2026-08-08 | PublicationSpatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats. | Phytomedicine : international journal of phytotherapy and phytopharmacology |
| 2026-08-08 | PublicationAtogepant Reduces Psychological Dependence on Acute Treatments Evaluated With the Leeds Dependence Questionnaire: A Prospective Study. | Brain and behavior |
| 2026-08-08 | PublicationReal-life effectiveness, tolerability, and safety of atogepant: a prospective, observational, multicentre study by the Headache Study Group in Castile-La Mancha. | Neurologia |
| 2026-08-08 | Publication[Pituitary adenylate-cyclase activating polypeptide (PACAP)-targeting treatment as a potential migraine prophylactic therapy]. | Ideggyogyaszati szemle |
| 2026-08-08 | PublicationRandomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. | Neurology |
| 2026-08-08 | PublicationRandomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. | Cephalalgia : an international journal of headache |
| 2026-08-08 | PublicationExpanding preventive options for pediatric migraine: the use of anti-CGRP monoclonal antibodies for children and adolescents with migraine. | Translational pediatrics |
| 2026-08-08 | PublicationTumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab. | European journal of pharmacology |
| 2026-08-08 | PublicationBlocking the CGRP Receptor: Differences across Human Vascular Beds. | Pharmaceuticals (Basel, Switzerland) |
| 2026-08-08 | PublicationCGRP receptor antagonists (gepants). | Handbook of clinical neurology |
| 2026-08-08 | PublicationReview: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine. | Current pain and headache reports |
| 2026-08-08 | PublicationPost-Craniotomy Headache: Current Concepts and Emerging Procedural Therapies. | Current pain and headache reports |
| 2026-08-08 | PublicationTwelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry. | The journal of headache and pain |
| 2026-08-08 | PublicationTargeting G-coupled GPCRs to inhibit nociceptors: Insights from the serotonin receptor Htr1b and triptans. | Cell reports. Medicine |
| 2026-08-08 | PublicationEfficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant. | Journal of oral & facial pain and headache |
| 2026-08-08 | Publication[Treatment persistence and adherence with botulinum toxin type A and anti-calcitonin gene-related peptide monoclonal antibodies in migraine. (A retrospective cohort study from a specialized headache center)]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |
| 2026-08-16 | Création de l’enregistrementNCT01924052 | Registre d’essai clinique |
| 2026-08-16 | PublicationBotulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research. | Journal of neural transmission (Vienna, Austria : 1996) |
| 2026-08-16 | PublicationDiscrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine. | Neurology and therapy |
| 2026-08-16 | PublicationNeuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting. | Annals of medicine |
| 2026-08-16 | Publication[Migraine in men: biological, psychosocial and clinical characteristics]. | Schmerz (Berlin, Germany) |
| 2026-08-16 | PublicationMolecular triggers of migraine aura: A systematic review of human pharmacological provocation studies. | Cephalalgia : an international journal of headache |
| 2026-08-16 | PublicationEfficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. | PloS one |
| 2026-08-16 | PublicationEarly Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery |
| 2026-08-16 | PublicationRimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project). | Cephalalgia : an international journal of headache |
| 2026-08-16 | PublicationXiongzhi Qufeng Zhitong Granule alleviates nitroglycerin-induced migraine-like nociception and central neuroinflammation by regulating the HMGB1 / TRPV1 / MAPK signaling axis. | Journal of ethnopharmacology |
| 2026-08-16 | PublicationPaeoniae Radix Alba-Chuanxiong Rhizoma herbal pair alleviates trigeminal nucleus caudalis neuroinflammation in chronic migraine associated with P2Y12R/PPARγ-related NF-κB signaling. | Journal of ethnopharmacology |
| 2026-08-16 | PublicationNeuro-Immune Axis in Trauma-Induced Heterotopic Ossification: Mechanisms and Therapeutic Implications. | Cells |
| 2026-08-16 | PublicationErenumab for Chronic Cluster Headache: A Randomized Clinical Trial. | JAMA network open |
| 2026-08-16 | PublicationEffects of erenumab on migraine aura frequency: a REFORM study. | The journal of headache and pain |
| 2026-08-16 | PublicationCGRP: the immune system's double agent - context-dependent roles in inflammation, resolution and cancer. | Frontiers in immunology |
| 2026-08-16 | PublicationEfficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE. | Neurology and therapy |
| 2026-08-16 | PublicationOnline interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. | Headache |
| 2026-08-16 | PublicationThe pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. | Headache |
| 2026-08-16 | PublicationElectroacupuncture at Jiaji points regulates splenic immunity and gut microbiota to ameliorate peripheral immune dysfunction after spinal cord injury. | Journal of neuroimmunology |
| 2026-08-16 | PublicationNXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. | Cephalalgia : an international journal of headache |
| 2026-08-16 | PublicationTolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. | The Lancet. Neurology |
| 2026-08-16 | PublicationRandomized, controlled trial of telcagepant over four migraine attacks. | Cephalalgia : an international journal of headache |
| 2026-08-16 | PublicationReal-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study. | Pain and therapy |
| 2026-08-16 | PublicationRandomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. | Neurology |
| 2026-08-16 | PublicationHalting neuron-fibroblast crosstalk disarms tumor and augments immunotherapy. | Trends in pharmacological sciences |
| 2026-08-16 | PublicationReal-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis. | Journal of medical economics |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT01924052 | CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load | Non applicable | COMPLETED | Non communiqué | Danish Headache Center |
Publications liées
47 publication(s)Publications liées
47 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research. Voir source | 40035830 | 10.1007/s00702-024-02869-w | Journal of neural transmission (Vienna, Austria : 1996) | |
| Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine. Voir source | 36848008 | 10.1007/s40120-023-00453-0 | Neurology and therapy | |
| Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting. Voir source | 41601146 | 10.1080/07853890.2026.2620337 | Annals of medicine | |
| [Migraine in men: biological, psychosocial and clinical characteristics]. Voir source | 41995752 | 10.1007/s00482-026-00935-8 | Schmerz (Berlin, Germany) | |
| Molecular triggers of migraine aura: A systematic review of human pharmacological provocation studies. Voir source | 41923467 | 10.1177/03331024261429112 | Cephalalgia : an international journal of headache | |
| Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2/3 trial. Voir source | 41779821 | 10.1371/journal.pone.0342907 | PloS one | |
| Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists. Voir source | 41774573 | 10.1002/ohn.70196 | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | |
| Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project). Voir source | 42405602 | 10.1177/03331024261462836 | Cephalalgia : an international journal of headache | |
| Xiongzhi Qufeng Zhitong Granule alleviates nitroglycerin-induced migraine-like nociception and central neuroinflammation by regulating the HMGB1 / TRPV1 / MAPK signaling axis. Voir source | 42398658 | 10.1016/j.jep.2026.122147 | Journal of ethnopharmacology | |
| Paeoniae Radix Alba-Chuanxiong Rhizoma herbal pair alleviates trigeminal nucleus caudalis neuroinflammation in chronic migraine associated with P2Y12R/PPARγ-related NF-κB signaling. Voir source | 42431281 | 10.1016/j.jep.2026.122177 | Journal of ethnopharmacology | |
| Neuro-Immune Axis in Trauma-Induced Heterotopic Ossification: Mechanisms and Therapeutic Implications. Voir source | 42121928 | 10.3390/cells15090827 | Cells | |
| Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial. Voir source | 40526384 | 10.1001/jamanetworkopen.2025.16318 | JAMA network open | |
| Effects of erenumab on migraine aura frequency: a REFORM study. Voir source | 41888647 | 10.1186/s10194-026-02338-7 | The journal of headache and pain | |
| CGRP: the immune system's double agent - context-dependent roles in inflammation, resolution and cancer. Voir source | 42488654 | 10.3389/fimmu.2026.1841366 | Frontiers in immunology | |
| Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE. Voir source | 42154195 | 10.1007/s40120-026-00961-9 | Neurology and therapy | |
| Online interest in calcitonin gene-related peptide-therapies: An infodemiology study using Google trends. Voir source | 42265869 | 10.1111/head.70136 | Headache | |
| The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. Voir source | 42265882 | 10.1111/head.70114 | Headache | |
| Electroacupuncture at Jiaji points regulates splenic immunity and gut microbiota to ameliorate peripheral immune dysfunction after spinal cord injury. Voir source | 42322789 | 10.1016/j.jneuroim.2026.579008 | Journal of neuroimmunology | |
| NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Voir source | 23155193 | 10.1177/0333102412466967 | Cephalalgia : an international journal of headache | |
| Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. Voir source | 42492556 | 10.1016/S1474-4422(26)00214-0 | The Lancet. Neurology | |
| Randomized, controlled trial of telcagepant over four migraine attacks. Voir source | 20974601 | 10.1177/0333102410370878 | Cephalalgia : an international journal of headache | |
| Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study. Voir source | 42098428 | 10.1007/s40122-026-00843-w | Pain and therapy | |
| Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Voir source | 17914062 | 10.1212/01.WNL.0000286940.29755.61 | Neurology | |
| Halting neuron-fibroblast crosstalk disarms tumor and augments immunotherapy. Voir source | 42067475 | 10.1016/j.tips.2026.03.006 | Trends in pharmacological sciences | |
| Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis. Voir source | 41725292 | 10.1080/13696998.2026.2630604 | Journal of medical economics | |
| Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine. Voir source | 40036725 | 10.1093/brain/awae344 | Brain : a journal of neurology | |
| CGRP-pathway exposure during the pre-EBP interval in spontaneous intracranial hypotension: an exploratory retrospective case series. Voir source | 42432562 | 10.1186/s12883-026-05172-1 | BMC neurology | |
| Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when? Voir source | 42493477 | 10.1080/14737175.2026.2706794 | Expert review of neurotherapeutics | |
| Spatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats. Voir source | 41619552 | 10.1016/j.phymed.2026.157815 | Phytomedicine : international journal of phytotherapy and phytopharmacology | |
| Atogepant Reduces Psychological Dependence on Acute Treatments Evaluated With the Leeds Dependence Questionnaire: A Prospective Study. Voir source | 42494172 | 10.1002/brb3.71553 | Brain and behavior | |
| Real-life effectiveness, tolerability, and safety of atogepant: a prospective, observational, multicentre study by the Headache Study Group in Castile-La Mancha. Voir source | 42532410 | 10.1016/j.nrleng.2026.502139 | Neurologia | |
| [Pituitary adenylate-cyclase activating polypeptide (PACAP)-targeting treatment as a potential migraine prophylactic therapy]. Voir source | 42554332 | 10.18071/isz.79.0223 | Ideggyogyaszati szemle | |
| Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Voir source | 25107879 | 10.1212/WNL.0000000000000771 | Neurology | |
| Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Voir source | 25926620 | 10.1177/0333102415584308 | Cephalalgia : an international journal of headache | |
| Expanding preventive options for pediatric migraine: the use of anti-CGRP monoclonal antibodies for children and adolescents with migraine. Voir source | 42433932 | 10.21037/tp-2026-0307 | Translational pediatrics | |
| Tumor expression of CGRP confers sensitivity to growth inhibition by the anti-CGRP antibody fremanezumab. Voir source | 42498203 | 10.1016/j.ejphar.2026.179151 | European journal of pharmacology | |
| Blocking the CGRP Receptor: Differences across Human Vascular Beds. Voir source | 37630989 | 10.3390/ph16081075 | Pharmaceuticals (Basel, Switzerland) | |
| CGRP receptor antagonists (gepants). Voir source | 38307667 | 10.1016/B978-0-12-823357-3.00033-1 | Handbook of clinical neurology | |
| Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine. Voir source | 39998706 | 10.1007/s11916-025-01365-4 | Current pain and headache reports | |
| Post-Craniotomy Headache: Current Concepts and Emerging Procedural Therapies. Voir source | 42554893 | 10.1007/s11916-026-01541-0 | Current pain and headache reports | |
| Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry. Voir source | 42533319 | 10.1186/s10194-026-02428-6 | The journal of headache and pain | |
| Targeting G-coupled GPCRs to inhibit nociceptors: Insights from the serotonin receptor Htr1b and triptans. Voir source | 42532046 | 10.1016/j.xcrm.2026.102949 | Cell reports. Medicine | |
| Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant. Voir source | 42548099 | 10.22514/jofph.2026.046 | Journal of oral & facial pain and headache | |
| [Treatment persistence and adherence with botulinum toxin type A and anti-calcitonin gene-related peptide monoclonal antibodies in migraine. (A retrospective cohort study from a specialized headache center)]. Voir source | 42565401 | 10.17116/jnevro202612607169 | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | |
| Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry. Voir source | 42410521 | 10.1186/s10194-026-02444-6 | The journal of headache and pain | |
| Long-term treatment with Eptinezumab in special treatment situations: Real world data. Voir source | 42442067 | 10.1016/j.jns.2026.126092 | Journal of the neurological sciences | |
| [Effect of electroacupuncture on chronic pain in patients with knee osteoarthritis and its influence on central sensitization]. Voir source | 42443077 | 10.13703/j.0255-2930.20250807-k0001 | Zhongguo zhen jiu = Chinese acupuncture & moxibustion |
Sources officielles
liens de rechercheDernière mise à jour des données : 2022-07-31
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.